Justin Mower
Overview
Explore the profile of Justin Mower including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu Y, Mower J, Ding X, Li O, Subramanian D, Cohen T
AMIA Annu Symp Proc
. 2023 May;
2022:1163-1172.
PMID: 37128462
Adverse event reports (AER) are widely used for post-market drug safety surveillance and drug repurposing, with the assumption that drugs with similar side-effects may have similar therapeutic effects also. In...
2.
Mower J, Bernstam E, Xu H, Myneni S, Subramanian D, Cohen T
AMIA Jt Summits Transl Sci Proc
. 2022 Jul;
2022:349-358.
PMID: 35854716
Although pharmaceutical products undergo clinical trials to profile efficacy and safety, some adverse drug reactions (ADRs) are only discovered after release to market. Post-market drug safety surveillance - pharmacovigilance -...
3.
Ding X, Mower J, Subramanian D, Cohen T
J Biomed Inform
. 2021 Jun;
119:103833.
PMID: 34111555
Adverse Drug Events (ADEs) are prevalent, costly, and sometimes preventable. Post-marketing drug surveillance aims to monitor ADEs that occur after a drug is released to market. Reports of such ADEs...
4.
Burkhardt H, Subramanian D, Mower J, Cohen T
AMIA Annu Symp Proc
. 2020 Apr;
2019:992-1001.
PMID: 32308896
The identification of drug-drug interactions (DDIs) is important for patient safety; yet, compared to other pharmacovigilance work, a limited amount of research has been conducted in this space. Recent work...
5.
Portanova J, Murray N, Mower J, Subramanian D, Cohen T
AMIA Annu Symp Proc
. 2020 Apr;
2019:717-726.
PMID: 32308867
Adverse event report (AER) data are a key source of signal for post marketing drug surveillance. The standard methodology to analyze AER data applies disproportionality metrics, which estimate the strength...
6.
Mower J, Cohen T, Subramanian D
Drug Saf
. 2019 Oct;
43(1):67-77.
PMID: 31646442
Introduction: As a result of the well documented limitations of data collected by spontaneous reporting systems (SRS), such as bias and under-reporting, a number of authors have evaluated the utility...
7.
Mower J, Subramanian D, Cohen T
J Am Med Inform Assoc
. 2018 Jul;
25(10):1339-1350.
PMID: 30010902
Objective: The aim of this work is to leverage relational information extracted from biomedical literature using a novel synthesis of unsupervised pretraining, representational composition, and supervised machine learning for drug...
8.
Mower J, Subramanian D, Shang N, Cohen T
AMIA Annu Symp Proc
. 2017 Mar;
2016:1940-1949.
PMID: 28269953
An important aspect of post-marketing drug surveillance involves identifying potential side-effects utilizing adverse drug event (ADE) reporting systems and/or Electronic Health Records. These data are noisy, necessitating identified drug/ADE associations...
9.
Almodovar J, Mower J, Banerjee A, Sarkar A, Ehrhart N, Kipper M
Biotechnol Bioeng
. 2012 Aug;
110(2):609-18.
PMID: 22903591
Cortical bone allografts suffer from high rates of failure due to poor integration with host tissue, leading to non-union, fracture, and infection following secondary procedures. Here, we report a method...